Randomized phase II trial of capecitabine and lapatinib with or without cixutumumab in patients with HER2+ breast cancer previously treated with trastuzumab and an anthracycline and/or a taxane: NCCTG N0733 (Alliance)

This article has no abstract
Epistemonikos ID: 3b9f49f0a0d6944b4c1c9283e8a049b61b19435c
First added on: Feb 06, 2025